Activated clotting time as a screening test prior to catheter-based cardiovascular procedures

Catheterization and Cardiovascular Interventions

Volumn 54, Issue 2, 2001, Pages 191-195

  Siskin, Gary P ^a,c   Reiner, Eric ^a   Stainken, Brian F ^b   Dowling, Kyran ^a   Dolen, Eric G ^a   Quarfordt, Steven ^b   Albons, Gom ^b  

^a ALBANY MEDICAL COLLEGE   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c ALBANY MEDICAL CENTER   (United States)

Author keywords

Angiography; Catheterization; Coagulation

Indexed keywords

ADULT; ANAMNESIS; ANGIOGRAPHY; APPARATUS; ARTICLE; BLEEDING; BLOOD CLOTTING DISORDER; BLOOD CLOTTING TEST; BLOOD CLOTTING TIME; CARDIOVASCULAR PROCEDURES; CLINICAL TRIAL; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; EVALUATION; FEMALE; HEART CATHETERIZATION; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PREDICTION; SCREENING TEST; SENSITIVITY AND SPECIFICITY;

BLOOD COAGULATION DISORDERS; BLOOD LOSS, SURGICAL; FEMALE; HEART CATHETERIZATION; HUMANS; MALE; MIDDLE AGED; PLATELET COUNT; POINT-OF-CARE SYSTEMS; PREDICTIVE VALUE OF TESTS; PREOPERATIVE CARE; PROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; WHOLE BLOOD COAGULATION TIME;

EID: 0034792364     PISSN: 15221946     EISSN: None     Source Type: Journal    
DOI: 10.1002/ccd.1265     Document Type: Article

References (35)

1. Abnormal coagulation profiles in tonsillectomy and adenoidectomy patients
2. Medical assessment of bleeding in the surgical patient
3. Complications after coronary angiography and balloon dilatation
4. Complications of percutaneous transaxillary catheterization for arteriography and selective chemotherapy
5. Preoperative laboratory screening in healthy Mayo patients: Cost-effective elimination of tests and unchanged outcomes
6. Evaluation of coagulation tests as predictors of angiographic bleeding complications
7. Hemostasis screening in the emergency laboratory
8. The preoperative bleeding time tests lacks clinical benefit: College of American Pathologists' and American Society of Clinical Pathologists' position article
9. A simple method of heparin management during prolonged extracorporeal circulation
10. Use of the activated coagulation time in intraoperative heparin reversal for cardiopulmonary operations
11. Control of heparinization by activated clotting time during bypass with improved postoperative hemostasis
12. Anticoagulation monitoring during cardiac surgery: A review of current and emerging techniques
13. The use of activated clotting times to monitor heparin therapy during and after interventional procedures
14. Adequate heparinization during PTCA: Assessment using activated clotting times
15. Clinical experience with routine activated coagulation time monitoring during elective PTCA
16. Monitoring the effect of heparin by measurement of activated clotting time during and after percutaneous transluminal coronary angioplasty
17. Use of the activated coagulation time as a measure of anticoagulation during interventional procedures
18. Anticoagulation control during neuroradiology interventions with ACT
19. Heparin: Mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety
20. Heparin therapy: Current regimens and principles of monitoring
21. Statistical correlation and heparin sensitivity of activated partial thromboplastin time, whole blood coagulation time, and an automated coagulation time
22. Bedside monitoring of heparin therapy: Comparison of activated clotting time to activated partial thromboplastin time
23. Oral anticoagulants: Mechanism of action, clinical effectiveness, and optimal therapeutic range
24. The international normalized ratio (INR): Hope for an uncertain result
25. Validation of a bedside method of activated partial thromboplastin time measurement with clinical range guidelines
26. Comparison of high-dose thrombin time with activated clotting time for monitoring of anticoagulant effects of heparin in cardiac surgical patients
27. Blood coagulation and autologous blood transfusion in cardiac surgery
28. Plasma activated clotting time as an indicator of dangerous hypocoagulability in warfarin-treated trauma patients: A preliminary study
29. How does warfarin affect the activated coagulation time?
30. When we "act" on ACT levels: Activated clotting time measurements to guide heparin administration during and after interventional procedures
31. Venous activated clotting time after intraarterial heparin: Effect of site of administration and timing of sampling
32. Relation between procedural activated coagulation time and outcome after percutaneous transluminal coronary angioplasty
33. Defining the optimal activated clotting time during percutaneous coronary intervention
34. Peripheral vascular complications after conventional and complex percutaneous coronary interventional procedures
35. Approach to the patient with a coagulopathy